SYS | | c011638 |
LBL | | ^^^^^nam^^22^^^^^^^^450^ |
005 | | 19970428000000.0 |
010 | | $a 0-521-41296-X |
100 | | $a 19941212d1993 u y0sloc0103 ba |
101 | 0- | $a eng |
102 | | $a GB |
105 | | $a a 0 0yy |
200 | 1- | $a Genetic factors in drug therapy $e Clinical and molecular pharmacogenetics $f David A. Evans |
210 | | $a Cambridge $c Cambridge University Press $d 1993 |
215 | | $a 23, 657 s. $c tab., graf., obr. |
541 | 0- | $a Genetické faktory vo farmakoterapii |
606 | | $a farmakoterapia $2 mesh $3 sllk_un_auth*d004358 |
606 | | $a farmakogenetika $2 mesh $3 sllk_un_auth*d010597 |
606 | | $a reakcia na dávku lieku $2 mesh $3 sllk_un_auth*d004305 |
606 | | $a systém enzýmov cytochrómu P-450 $2 mesh $3 sllk_un_auth*d003577 |
606 | | $a karcinóm bronchogénny $2 mesh $3 sllk_un_auth*d002283 |
606 | | $a cyklosporíny $2 mesh $3 sllk_un_auth*d003524 |
606 | | $a cholínesterázy $2 mesh $3 sllk_un_auth*d002802 |
606 | | $a pitie alkoholu $2 mesh $3 sllk_un_auth*d000428 |
606 | | $a prípravky farmaceutické $x metabolizmus $2 mesh $3 sllk_un_auth*d004364 |
606 | | $a hypertermia malígna $2 mesh $3 sllk_un_auth*d008305 |
606 | | $a chloramfenikol $2 mesh $3 sllk_un_auth*d002701 |
606 | | $a lekárstvo pracovné $2 mesh $3 sllk_un_auth*d009787 |
606 | | $a farmakoterapia $2 mesh $3 sllk_un_auth*d004358 |
606 | | $a farmakogenetika $2 mesh $3 sllk_un_auth*d010597 |
606 | | $a cholínesterázy $2 mesh $3 sllk_un_auth*d002802 |
606 | | $a sukcinylcholín $2 mesh $3 sllk_un_auth*d013390 |
606 | | $a porfýrie $2 mesh $3 sllk_un_auth*d011164 |
675 | | $a 615.2:575.1 $v 1. stred. $z slo |
700 | -1 | $a Evans $b David A. $3 sllk_un_auth*p0011067 $4 070 |
801 | -0 | $a SK $b BA006 $c 19981223 $g AACR2 |